Indexing hint: Observational study · 2025
Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
Smolderen et al. 2025Diabetes, obesity & metabolismcited by 9
PMID 40926360PMC12515752DOI 10.1111/dom.70080PUB-40926360